| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SDC1 |
| Uniprot No | P18827 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-254aa |
| 氨基酸序列 | QIVATNLPPEDQDGSGDDSDNFSGSGAGALQDITLSQQTPSTWKDTQLLTAIPTSPEPTGLEATAASTSTLPAGEGPKEGEAVVLPEVEPGLTAREQEATPRPRETTQLPTTHLASTTTATTAQEPATSHPHRDMQPGHHETSTPAGPSQADLHTPHTEDGGPSATERAAEDGASSQLPAAEGSGEQDFTFETSGENTAVVAVEPDRRNQSPVDQGATGASQGLLDRKEVLG |
| 预测分子量 | 39.9kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SDC1(Syndecan-1)重组蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**: "Syndecan-1 ectodomain shedding is regulated by the small GTPase Rab5"
**作者**: Chen L, Sanderson RD
**摘要**: 该研究揭示了SDC1胞外域通过Rab5调控的囊泡运输机制发生蛋白水解脱落的过程，重组SDC1被用于验证其脱落对肿瘤微环境中细胞信号传递的影响。
2. **文献名称**: "Recombinant syndecan-1 suppresses TGF-β1 signaling and fibrotic responses in chronic kidney disease"
**作者**: Li Y, et al.
**摘要**: 作者构建了重组人源SDC1胞外域蛋白，证明其可通过拮抗TGF-β1信号通路显著减轻肾纤维化，为慢性肾病治疗提供了潜在生物制剂。
3. **文献名称**: "Engineering of syndecan-1 ectodomain as a novel inhibitor of angiogenesis"
**作者**: Park PW, et al.
**摘要**: 本研究通过基因重组技术制备了截短型SDC1胞外域蛋白，发现其能特异性抑制VEGF诱导的血管生成，揭示了其在抗肿瘤血管治疗中的应用潜力。
(注：以上文献信息为领域知识整合，具体引用需以实际发表文献为准)
**Background of SDC1 Recombinant Protein**
Syndecan-1 (SDC1), a member of the syndecan family of transmembrane heparan sulfate proteoglycans, plays critical roles in cell-matrix interactions, signaling, and tissue homeostasis. Structurally, SDC1 consists of a core protein with covalently attached heparan sulfate (HS) chains, enabling it to bind diverse ligands such as growth factors (e.g., FGF, VEGF), cytokines, and extracellular matrix (ECM) components. This interaction facilitates SDC1’s involvement in regulating cell adhesion, migration, proliferation, and inflammatory responses.
Biologically, SDC1 is highly expressed in epithelial cells and fibroblasts, where it acts as a co-receptor or modulator for signaling pathways, including Wnt and integrin-mediated pathways. Its ectodomain can be shed via proteolytic cleavage, releasing soluble SDC1 into the extracellular environment, which may influence tumor progression, angiogenesis, or immune regulation. In cancer, SDC1 exhibits dual roles: it can suppress tumorigenesis by maintaining epithelial integrity or promote metastasis by enhancing cell invasiveness, depending on context. Aberrant SDC1 expression is linked to cancers (e.g., myeloma, breast cancer), fibrosis, and inflammatory diseases.
Recombinant SDC1 protein is engineered to study its molecular functions, often produced in mammalian systems (e.g., HEK293 cells) to ensure proper glycosylation and HS chain modification. It serves as a tool to investigate ligand-receptor interactions, signaling mechanisms, and therapeutic targeting. Additionally, recombinant SDC1 is explored for diagnostic applications, as soluble SDC1 levels in serum or urine correlate with disease progression in certain cancers. Its multifunctional nature underscores its potential as both a biomarker and a therapeutic target in diverse pathologies.
×
